Comparison of Outcomes between Brachytherapy and Intensity Modulated Radiotherapy in High Risk Prostate Cancer M. A. Weller, C. A. Reddy, J. Kittel, K.

Slides:

Advertisements

Similar presentations

Impact of cytokeratin-positive cells in bone marrow on survival in patients with non-metastatic prostate cancer treated by radiotherapy PURPOSE To evaluate.

Advertisements

PROSTATE CANCER Dr Samad Zare Assistant Proffesor of Urology Shaheed Sadoughi University of Medical Sciences.

Introduction Treatment of metastatic prostate cancer with androgen deprivation therapy (ADT) is effective, but can be associated with debilitating side.

Radiation Therapy for Treatment of Prostate Cancer Stephen Ko, M.D. Mayo Clinic Florida August 30, 2010.

Radiotherapy in prostate cancer Dr.Mina Tajvidi Radiation oncologist.

Steven Joniau Filip Ameye

Dobson DaVanzo & Associates, LLC Vienna, VA Prostate Cancer Patients Report on Benefits of Proton Therapy: Follow- on.

Prostate Cancer Int. 洪毓謙. Prostate cancer is the Second leading cause of death from cancer in the United States American male, the lifetime risk of:

Controversies in the management of PSA-only recurrent disease Stephen J. Freedland, MD Associate Professor of Urology and Pathology Durham VA Medical Center.

 These slides were extracted from a larger set of comprising a presentation entitled “Comparing Treatment Results of PROSTATE CANCER” dated 15_01_2013(3).

Treatment options for locally recurrent Prostate Cancer Giuseppe Simone Mediterranean School of Oncology Roma

Radiotherapy - the art of the invisible Terry Kehoe Consultant Clinical Scientist Head of Oncology Physics Edinburgh Cancer Centre “How to crack a walnut”

Surrogate End point for Prostate Cancer- Specific Mortality After RP or EBRT A D’Amico J Nat Ca Inst 95,

Low dose chemotherapy with insulin (Insulin Potentiation Therapy) in combination with hormone therapy for treatment of castration resistant prostate cancer.

Dan Spratt, MD Department of Radiation Oncology Neuroendocrine Prostate Cancer: FDG-PET and Targeted Molecular Imaging.

Prostate Cancer: A Case for Active Surveillance Philip Kantoff MD Dana-Farber Cancer Institute Professor of Medicine Harvard Medical School.

The PCA3 Assay improves the prediction of initial biopsy outcome and may be indicative of prostate cancer aggressiveness de la Taille A, Irani J, Graefen.

Clinico-Dosimetric Correlation for Acute and Chronic Gastrointestinal Toxicity in Patients of Locally Advanced Carcinoma Cervix Treated With Conventional.

Updated 5-year Biochemical Relapse-Free Survival after Prostate Brachytherapy Jenny P. Nobes St. Luke’s Cancer Centre, The Royal Surrey County Hospital,

Radiologic Assessment of the Genitourinary Diaphragm Using MRI with Endorectal Coil in Men with Localized Prostate Cancer ASTRO Annual Meeting 2014, #3792.

PROSTATE CANCER: RADIATION THERAPY APPROACHES ANDREW L. SALNER, MD FACR DIRECTOR HELEN & HARRY GRAY CANCER CENTER HARTFORD HOSPITAL, CT.

Prostate Cancer: Treatment choices Prostate Cancer: Treatment choices Winston W Tan MD FACP Winston W Tan MD FACP Senior Consultant Senior Consultant Genitourinary.

A prospective randomized trial

Prostate Cancer Screening Risk Management Ben Inch.

Prognosis study EBM questions. Prognostic factors Characteristics of patient that may predict eventual outcome Several types: demographic (eg age) disease-specific.

Introduction/Aims There is less written about failure patterns after prostate brachytherapy (BT) alone or in combination with external beam radiotherapy.

FREEDOM FROM PROGRESSION FOR PATIENTS RECEIVING I 125 VERSUS Pd 103 FOR PROSTATE BRACHYTHERAPY Jane Cho, Carol Morgenstern, Barbara Napolitano, Lee Richstone,

High Dose Rate Brachytherapy Boost for Prostate Cancer: Comparison of Two Different Fractionation Schemes Tania Kaprealian 1, Vivian Weinberg 3, Joycelyn.

Table 1. Characteristics of patients and the results of the log-rank test of prognostic factors Median (range) No. of patients No. of CRPC Median progression.

Immediate vs. deferred initiation of androgen deprivation therapy in prostate cancer patients with PSA-only relapse. An observational follow-up study Presented.

Combined Modality Treatment of Locally Advanced Prostate Cancer: Radiation Therapy (RT) with Concurrent Androgen Deprivation Therapy (ADT) Howard Sandler.

National Cancer Intelligence Network Outcome and the effect of age in 1318 patients with synovial sarcoma: Report from the National Cancer Intelligence.

New developments in Prostate Cancer Dr Jo Bowen Consultant Oncologist Worcestershire Royal Hospital.

IMPACT OF STAGE MIGRATION ON NODE POSITIVE PROSTATE CANCER RATE AND FEATURES: A 20-YEAR, SINGLE INSTITUTION ANALYSIS IN MEN TREATED WITH EXTENDED PELVIC.

HOW TO WRITE THE RESULTS SECTION

Radiation therapy for Early Stage Prostate Cancer

New developments in Prostate Cancer

STAMPEDE: Docetaxel Significantly Improves Survival in Men With Hormone-Naive Prostate Cancer CCO Independent Conference Highlights of the 2015 ASCO Annual.

Bladder Cancer and Prostatic Cancer

Treatment Stage Migration Maximizes Survival Outcomes in Patients with Hepatocellular Carcinoma Treated with Sorafenib: An Observational Study Liver Cancer.

The Role of Radical Prostatectomy and Radiotherapy in Treatment of Locally Advanced Prostate Cancer: A Systematic Review and Meta-Analysis Urol Int 2017;99:

As is shown, men treated by radical prostatectomy had a better adjusted survival rate than men without prostate cancer suggesting selection biases for.

RELAZIONE TRA “STAGE MIGRATION” E

Figure 1. The (a) anterior–posterior and (b) right-lateral fields and (c, d) the isodose distributions of two axial planes in one patient with T2 stage.

RTOG 0126 A Phase III Randomized Study of High Dose 3D-CRT/IMRT versus Standard Dose 3D-CRT/IMRT in Patients Treated for Localized Prostate Cancer Bijoy.

Volume 74, Issue 4, Pages (October 2018)

Prostate Cancer: Highlights from 2006

Claude C. Schulman, Jacques Irani, Juan Morote, Jack A

Development and internal-external validation of a multivariable prediction model for pre-operative assessment of positive lymph nodes during robot assisted.

Insert tables Insert graphs Insert figure

Volume 71, Issue 5, Pages (May 2017)

Hormone Therapy for Prostate Cancer: Exploring Current Controversies

Supplemental Figure 1: Kaplan-Meier Curves of overall survival based on clinical stage at presentation and treatment modality Kaplan-Meier analyses depicting.

Volume 74, Issue 1, Pages (July 2018)

Ongoing Gleason Grade Migration in Localized Prostate Cancer and Implications for Use of Active Surveillance Adam B. Weiner, Ruth Etzioni, Scott E. Eggener

Volume 67, Issue 6, Pages (June 2015)

Volume 71, Issue 5, Pages (May 2017)

Volume 64, Issue 6, Pages (December 2013)

External Beam Radiotherapy as Curative Treatment of Prostate Cancer

Current Status of Combined Radiation Therapy and Androgen Suppression in Locally Advanced Prostate Cancer: What Is the Way Forward? Michel Bolla European.

Risk Factors for the Development of Bone Metastases in Prostate Cancer

Bone Health in Patients With Prostate Cancer: Monitoring and Diagnosis

Long-Term Hormonal Therapy: Who Would Benefit?

Genomic Testing: When and Why

Improving Outcomes in Prostate Cancer: Time to Tackle Bone Disorders

Evaluating the prevalence and predictive factors of vasomotor and psychological symptoms in prostate cancer patients receiving hormonal therapy: Results.

Volume 53, Issue 6, Pages (June 2008)

Management of Prostate Cancer: Global Strategies

Prostate Radiotherapy for Metastatic Hormone-sensitive Prostate Cancer: A STOPCAP Systematic Review and Meta-analysis Sarah Burdett, Liselotte M. Boevé,

Oncoforum Urology: Prostate Cancer 2008 at a Glance

Presentation transcript:

Comparison of Outcomes between Brachytherapy and Intensity Modulated Radiotherapy in High Risk Prostate Cancer M. A. Weller, C. A. Reddy, J. Kittel, K. Smith, R. D. Tendulkar, K. L. Stephans, E. A. Klein, K. W. Angermeier, J. Ulchaker, S. Campbell, A. Stephenson, J. P. Ciezki 1. Cleveland Clinic, Cleveland, OH

Purpose/Methods To study the outcomes in patients treated for high risk prostate cancer (PCA) with low-dose-rate brachytherapy (BT), in comparison to those treated with dose-escalated intensity modulated radiotherapy (IMRT) in combination with androgen deprivation therapy (ADT) 453 patients with high risk (NCCN criteria) PCA treated between 1997 and 2010 at a single institution: – 295 (65%) patients were treated with BT with or without ADT – 158 (35%) patients were treated with IMRT and ADT

Survival Curves and MVAs

Conclusions After adjusting for stage, PSA, Gleason Score, and ADT use, there was no difference in bRFS or DMFS between patients treated with brachytherapy compared to those treated with IMRT in combination with ADT On multivariate analysis, Gleason score was the only factor that significantly predicted for distant metastases Further study is warranted to validate this approach